Literature DB >> 10030784

Management of asthma and COPD patients: feasibility of the application of guidelines in general practice.

M P Jans1, F G Schellevis, W van Hensbergen, T Dukkers van Emden, J T van Eijk.   

Abstract

OBJECTIVE: To examine the feasibility of the application of guidelines to the management of asthma and chronic obstructive pulmonary disease (COPD) by assessing compliance with the guidelines and listing the barriers general practitioners (GPs) encountered during implementation. Insight into the feasibility of individual items in the guidelines can guide implementation strategies in the future and, if necessary, support revision of the guidelines.
DESIGN: Descriptive study of care delivered during the implementation of guidelines by means of documentation of the care provided, education, feedback on compliance and peer review.
SETTING: General practice. STUDY PARTICIPANTS: Sixteen GPs in 14 general practices. MAIN OUTCOME MEASURES: Compliance was expressed as the percentage of patients per practice managed by the GPs according to the guidelines. For each patient (n=413) data were collected on the care delivered during the first year of the implementation. Barriers encountered were derived from the summaries of the discussions held during the monthly meetings.
RESULTS: The GPs were most compliant on the items 'PEFR measurement at every consultation' (98%), 'allergy test' (78%) and 'advice to stop smoking' (82%), and less compliant on the items 'four or more consultations a year' (46%), 'ordering spirometry' (33%), 'adjustment of medication' (42%), 'check on inhalation technique' (38%) and referral to a chest physician (17%) or a district nurse (5%). The main barriers were the amount of time to be invested, doubts about the necessity of regular consultations and about the indications for ordering spirometry and for referral to a chest physician or a district nurse.
CONCLUSION: Although the feasibility was assessed in a fairly optimal situation, compliance with the guidelines was not maximal, and differed between the individual items of care. Suggestions are given for further improvements in compliance with the guidelines and for revision of the guidelines.

Entities:  

Mesh:

Year:  1998        PMID: 10030784     DOI: 10.1093/intqhc/10.1.27

Source DB:  PubMed          Journal:  Int J Qual Health Care        ISSN: 1353-4505            Impact factor:   2.038


  5 in total

1.  Interdisciplinary model of care (RADICALS) for early detection and management of chronic obstructive pulmonary disease (COPD) in Australian primary care: study protocol for a cluster randomised controlled trial.

Authors:  Jenifer Liang; Michael J Abramson; Nicholas Zwar; Grant Russell; Anne E Holland; Billie Bonevski; Ajay Mahal; Benjamin van Hecke; Kirsten Phillips; Paula Eustace; Eldho Paul; Kate Petrie; Sally Wilson; Johnson George
Journal:  BMJ Open       Date:  2017-09-18       Impact factor: 2.692

2.  Diagnosis of airway obstruction in primary care in the UK: the CADRE (COPD and Asthma Diagnostic/management REassessment) programme 1997-2001.

Authors:  Mike Pearson; Jon G Ayres; Maria Sarno; Dan Massey; David Price
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2006

3.  Developing a questionnaire to identify perceived barriers for implementing the Dutch physical therapy COPD clinical practice guideline.

Authors:  Philip J van der Wees; Cor A M Zagers; Sara E de Die; Erik J M Hendriks; Maria W G Nijhuis-van der Sanden; Rob A de Bie
Journal:  BMC Health Serv Res       Date:  2013-05-01       Impact factor: 2.655

4.  Antibiotics used in the ambulatory management of acute COPD exacerbations.

Authors:  Marie-France Beauchesne; Marcel Julien; Louis-André Julien; Dominique Piquette; Amélie Forget; Manon Labrecque; Lucie Blais
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2008

5.  A systematic review of the implementation and impact of asthma protocols.

Authors:  Judith W Dexheimer; Elizabeth M Borycki; Kou-Wei Chiu; Kevin B Johnson; Dominik Aronsky
Journal:  BMC Med Inform Decis Mak       Date:  2014-09-09       Impact factor: 2.796

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.